Radiation recall dermatitis

International Journal of Dermatology

Volumn 43, Issue 9, 2004, Pages 627-631

  Ristić, Biljana ^a  

^a University Clinical Hospital Center Bezanijska Kosa   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIOXIDANT; CYTOTOXIC AGENT; STEROID;

BLOOD VESSEL INJURY; CLINICAL FEATURE; DRUG SENSITIVITY; EPITHELIUM CELL; HUMAN; HYPOTHESIS; PATHOGENESIS; RADIATION DERMATITIS; RADIATION EXPOSURE; REVIEW; STEM CELL;

EID: 4644281310     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02406.x     Document Type: Review

References (32)

1. D'Angio G, Farber S, Maddock C. Potentiation of x-ray effects by actinomycin-D. Radiology 1959; 73: 175-177.
2. Camidge R, Price A. Characterizing the phinomenon of radiation recall dermatitis. Radiother Oncol 2001; 59: 237-245.
3. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002; 53: 394-400.
4. Kharfan Dabaja MA, Morgensztern D, Markoe AM, et al. Radiation recall dermatitis induced by methotrexate in a patient with Hodgkin's disease. Am J Clin Oncol 2000; 23: 531-533.
5. Yeo W, Johnson PJ. Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence and management. Am J Clin Dermatol 2000; 1: 113-116.
6. Schwitzer VG, Juillard GJ, Bajada CL, et al. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76: 1069-1072.
7. Hill AB, Tattersall SF. Recall of radiation pneumonitis after intrapleural administration of doxorubicin. Med J Aust 1983; 11: 39-40.
8. Bostrom A, Sjolin-Forsberg G, Wilking N, et al. Radiation recall - another call with tamoxifen. Acta Oncol 1999; 38: 955-959.
9. Thomas R, Stea B. Radiation recall dermatitis from high dose interferon alfa-2b. J Clin Oncol 2002; 20: 355-357.
10. Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: a new observation. Clin Oncol (R Coll Radiol) 1995; 7: 325-526.
11. Extermarm M, Vogt N, Forni M, et al. Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol 1994; 48: 77-78.
12. Gabel C, Eifel PJ, Tornos C, et al. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol 1995; 57: 266-269.
13. Wallenborn PA 3rd, Postma DS. Radiation recall supraglottitis. A hazard in head and neck chemotherapy. Arch Otolaryngol 1984; 110: 614-617.
14. Tan CTC, Dargeon HW, Burchenal JH. The effect of actinomycin D on cancer in childhood. Pediatrics 1959; 24: 544-561.
15. Stelzer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71: 1322-1325.
16. Kuku I, Kaya E, Sevinc A, et al. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. JEADV 2002; 16: 271-272.
17. Valentin J. Avoidance of radiation injuries from medical interventional procedures. Ann ICRP 2000; 30: 7-67.
18. Castellano D, Hitt R, Cortes-Funes H, et al. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18: 695-696.
19. Yeo W, Leung SF, Johnson PJ. Radiation recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33: 698-699.
20. Bar-Sela G, Beny A, Bergman R, et al. Gemcitabine-induced radiation recall dermatitis: case report. Tumori 2001; 87: 428-430.
21. Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002; 00: 00-00.
22. Martin M, Lefaix JL, Delanian S. TGF-β1 and radiation fibrosis. a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000; 47: 277-290.
23. Gruber BL, Marchese MJ, Kew RR. Transforming growth factor-β1 mediates mast cell chemotaxis. J Immunol 1994; 152: 5860-5867.
24. Olsson N, Piek E, ten Dijke P, et al. Human mast cell migration in response to members of the transforming growth factor-beta family. J Leukoc Biol 2000; 67: 350-356.
25. Toyota N, Hashimoto Y, Matsuo S, et al. Transforming growth factor beta 1 inhibits IL-3 and IL-4 dependent mouse connective tissue-type mast cell proliferation. Arch Dermatol Res 1995; 287: 198-201.
26. Richter KK, Langberg CW, Sung CC, et al. Increased transforming growth factor beta (TGF-beta) immunoreactivity is independently associated with chronic injury in both consequential and primary radiation enteropathy. Int J Radiat Oncol Biol Phys 1997; 39: 187-195.
27. Aldenborg F, Nilsson K, Jarlshammar B, et al. Mast cells and biogenic amines in radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1993; 8: 112-117.
28. Gilchrist M, Savoie M, Nohara O, et al. Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. J Leukoc Biol 2002; 71: 618-624.
29. Bidri M, Feger F, Varadaradjalou S, et al. Mast cells as a source and target for nitric oxide. Int Immunopharmacol 2001; 1: 1543-1558.
30. Forsythe P, Gilchrist M, Kulka M, et al. Mast cells and nitric oxide: control of production, mechanisms of response. Int Immunopharmacol 2001; 1: 1525-1541.
31. Coleman JW. Nitric oxide in immunity and inflammation. Int Immunopharmacol 2001; 1: 1397-1406.
32. Kim PKM, Zamora R, Petrosko P, et al. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001; 1: 1421-1441.